NautaDutilh advised the Underwriters - BofA Merrill Lynch, Cowen and Company, LLC, Canaccord Genuity and BTIG - on all Belgian law matters with respect to the initial public offering in the United States by TiGenix NV (Euronext Brussels: TIG; "TiGenix") of 2,300,000 American Depository Shares ("ADSs"), representing 46,000,000 ordinary shares, at a price of USD 15.50 per ADS totalling USD 35.65 million gross proceeds.
Goodwin Procter LLP acted as US counsel to the underwriters.
In connection with the Offering, TiGenix has granted the underwriters a 30-day option to purchase up to an additional 345,000 ADSs, representing 6,900,000 ordinary shares, to cover over-allotments, if any. The closing of the Offering is expected to occur on December 20, 2016, subject to the satisfaction of customary closing conditions. In November 2015 and March 2016 we have assisted the underwriters with private placements by TiGenix of respectively € 8.7 million and € 23.75 million.
TiGenix is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells. Its ordinary shares are currently listed on Euronext Brussels. The ADSs are expected to begin trading on NASDAQ on December 15, 2016 under the symbol "TIG".
Dirk Van Gerven acted as responsible partner and the team was led by Maxime Colle and consisted of Louis Lantonnois and Christel Brion.
For more information, please see TiGenix's official press release.